The purpose of this study is to demonstrate the efficacy and safety of ziltivekimab in reducing the risk of major cardiovascular events when initiated as soon as possible in adult patients who have had a heart attack. Ziltivekimab is a medication designed to reduce inflammation after a heart attack, and thereby reduce secondary cardiac events.
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with chronic graft-versus-host disease.
The purpose of this study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis who are 18 to 55 years of age at the time of enrollment.
The purpose of this study is to collect biospecimens (fecal, urine, blood) and clinical data to serve as a resource for future research on Parkinson’s disease and other movement disorders. The careful collection, storage and retrieval of biospecimens and medical information for research projects are critical for improving understanding of healthy development and disease mechanisms and the subsequent development of effective treatments. Biospecimens from this biobank will be made available for ethically-approved studies.
The purpose of this study is to evaluate the immune response and safety of a new vaccine in preventing diseases due to infection with respiratory syncytial virus (RSV). This RSV vaccine will be tested in older adults who are recipients of lung or kidney transplants and are at an increased risk of RSV compared to healthy older adults.
The purpose of this study is to assess the efficacy of two dose levels of brepocitinib in adults with dermatomyositis compared to a placebo. After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52-week, open-label extension phase where all participants will receive brepocitinib.
The purpose of this study is to test the ability of a new immune modulator, QBKPN, to boost natural immunity to improve health, including reducing respiratory infections. It will also measure the effect of QBKPN on non-respiratory infections, quality of life and overall survival.
The purpose of this study is to characterize a recipient's immune system response to kidney transplantation to uncover an immune signature of early graft rejection.
The purpose of this study is to establish a protocol for improved human leukocyte antigen (HLA) matching for renal transplant patients.
The purpose of the study is to investigate the safety and efficacy of itolizumab versus placebo in individuals with acute graft-versus-host disease, when combined with corticosteroids as a first line treatment.
The purpose of this study is evaluate the safety and efficacy of a new vaccine to protect children against bacteria that can lead to pneumococcal disease.
The purpose of the study is to identify immune cells and antibodies that fight the novel coronavirus (SARS-CoV-2) from individuals who have been infected and recovered from COVID-19. Neutralizing antibodies will be used for the development of new therapies and diagnostic tools for COVID-19
The purpose of the main study is to investigate adverse drug reactions from multiple sclerosis (MS) disease modifying drugs by understanding the genetic factors that contribute to their cause.
The sub-study investigates how the MS disease modifying drugs affect microbes in the gut and how human DNA affects the changes in the gut microbes following drug treatment. We are also interested in how gut microbes might relate to progressive MS.
The purpose of this study is to determine whether an online patient passport tool called the Arthritis Health Journal can assist people with rheumatoid arthritis in managing their disease.
The purpose of this study is to evaluate the efficacy, safety and tolerability of axatilimab at three different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least two prior lines of systemic therapy.
The purpose of this study is to evaluate an investigational vaccine that may protect children between 6 months and 11 years old from getting sick if they come into contact with SARS-CoV-2, the virus that causes COVID-19.
The purpose of this study is to examine the safety and efficacy of a steriod called ciclesonide in treating mild covid-19 disease.
The purpose of this study is to explore certain aspects of the blood and brain to determine how a person may recover from COVID-19. In addition, this study will examine how the different aspects of COVID-19 may affect how a person thinks or feels.
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL).
To identify the clinical, social and cultural determinants of late HAART initiation and to determine the impact of HIV-related care (routine access to care, physician experience, physical and social barriers to care) and use of community-based organizations on HAART uptake and retention.